Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

The $200 Popcorn Popper That Keeps Selling Out

October 1, 2026

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Global Oligonucleotide Synthesis Market Analysis and Opportunity Forecast 2023-2028 – RNA-based Therapeutics Show Promise, Boosting Demand for Tailored Oligonucleotides
Press Release

Global Oligonucleotide Synthesis Market Analysis and Opportunity Forecast 2023-2028 – RNA-based Therapeutics Show Promise, Boosting Demand for Tailored Oligonucleotides

By News RoomJanuary 10, 20244 Mins Read
Global Oligonucleotide Synthesis Market Analysis and Opportunity Forecast 2023-2028 – RNA-based Therapeutics Show Promise, Boosting Demand for Tailored Oligonucleotides
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 10, 2024 (GLOBE NEWSWIRE) — The “Global Oligonucleotide Synthesis Market – Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028” report has been added to ResearchAndMarkets.com’s offering.

The Global Oligonucleotide Synthesis Market, valued at USD 4.03 billion in 2022, is anticipated to experience robust growth in the forecast period, with an expected Compound Annual Growth Rate (CAGR) of 13.3% through 2028.

This market holds a significant position in the biotechnology and pharmaceutical industries, serving as a vital intersection for cutting-edge research and therapeutic development. The remarkable expansion in recent years is driven by the increasing demand for custom-designed oligonucleotides across diverse applications, including gene editing, molecular diagnostics, and drug discovery.

Genomics, personalized medicine, and RNA-based therapeutics contribute to this surge, relying heavily on precise oligonucleotide synthesis. The market’s competitive landscape features established leaders and innovative startups, with technological advancements enhancing production efficiency. Regulatory approvals and industry standards play a crucial role in ensuring quality and safety.

Key Market Drivers:

  1. RNA-based Therapeutics:
    • RNA-based therapeutics, including mRNA vaccines and gene therapies, heavily rely on precise oligonucleotide synthesis.
    • The success of mRNA vaccines has led to increased demand for custom oligonucleotides, driving market growth.
    • RNA-based therapeutics show promise in treating genetic disorders, cancers, and rare diseases, further boosting demand for tailored oligonucleotides.
  2. Advancements in Genomic Research:
    • Next-Generation Sequencing (NGS) and CRISPR-Cas9 gene editing have fueled genomic research, increasing the demand for custom-designed oligonucleotides.
    • Oligonucleotides are essential for whole-genome sequencing, gene expression profiling, and functional genomics, supporting researchers in decoding genetic material.

Key Market Challenges:

  1. Efficiency and Scalability:
    • Meeting the escalating demand for custom oligonucleotides poses challenges in terms of efficiency and scalability.
    • Balancing fast, precise, and error-free synthesis processes with the need for scalability is crucial.
    • The synthesis of long or highly modified oligonucleotides may require specialized equipment, impacting efficiency.
  2. Cost Constraints:
    • Cost constraints affect both research and commercial applications of oligonucleotides.
    • High expenses associated with the synthesis of long or chemically modified sequences can be prohibitive.
    • Maintaining competitive pricing while ensuring quality and customization remains challenging for companies.

Key Market Trends:

  1. Therapeutic Advancements:
    • RNA-based therapeutics, including mRNA vaccines and gene therapies, drive a new era in precision medicine.
    • Oligonucleotide synthesis enables the production of synthetic RNA molecules critical for therapeutic efficacy.
    • The market contributes to transformative advancements in healthcare, emphasizing the importance of staying technologically advanced.
  2. Gene Editing and CRISPR-Cas9:
    • Gene editing, particularly through CRISPR-Cas9, is a major driver, relying on precise oligonucleotide synthesis.
    • Custom-designed oligonucleotides, such as guide RNAs (gRNAs), are crucial for targeting and modifying specific DNA sequences.
    • As gene editing expands in various fields, the market is poised for substantial growth.

Segmental Insights:

  1. Application Insights:
    • The Therapeutic Segment dominates the market, driven by the surge in RNA-based therapeutics and personalized medicine.
    • Custom-designed oligonucleotides are essential for gene editing, RNA interference, and precision medicine approaches.
    • Regulatory approvals and research collaborations further propel the therapeutic segment’s expansion.
  2. Regional Insights:
    • North America leads the market, supported by a robust pharmaceutical and biotechnology industry, substantial investment in healthcare research, and a favorable regulatory environment.
    • The region’s emphasis on precision medicine aligns with the demand for customized oligonucleotides.
    • Well-established infrastructure ensures efficient supply chains and timely delivery of oligonucleotides.

Key Market Players:

  1. Thermo Fisher Scientific Inc.
  2. Agilent Technologies, Inc.
  3. Merck KGaA
  4. BIO-Synthesis Inc.
  5. Eurofins Scientific SE
  6. Danaher Corporation
  7. Biogen Inc.
  8. Ionis Pharmaceuticals, Inc.
  9. Sarepta Therapeutics, Inc.

Report Scope

The report covers the Oligonucleotide Synthesis Market with detailed segmentation based on product type, application, end-user, and region. It provides comprehensive insights into industry trends, challenges, and key players, offering a thorough analysis of the market landscape.

This comprehensive report on the Global Oligonucleotide Synthesis Market provides a detailed understanding of its current state, key drivers, challenges, trends, and the competitive landscape. It covers crucial aspects such as market overview, key drivers, challenges, trends, key market players, and regional insights. Additionally, the report delves into segmental analysis, focusing on product type, application, end-user, and region. The competitive landscape section profiles key players, offering a detailed analysis of their business strategies, product offerings, and market presence.

Key Attributes

Report Attribute Details
No. of Pages 183
Forecast Period 2022-2028
Estimated Market Value (USD) in 2022 $4.03 Billion
Forecasted Market Value (USD) by 2028 $8.52 Billion
Compound Annual Growth Rate 13.3%
Regions Covered Global

For more information about this report visit https://www.researchandmarkets.com/r/ch2fz1

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Oligonucleotide Synthesis Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

The $200 Popcorn Popper That Keeps Selling Out

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

Easy Environmental Solutions Ships First Commercial EasyFEN™ System to Kenya

The News Forum Presents Aftershock: The World After October 7, 2023

BloFin returns as TOKEN2049 Singapore title sponsor, opens its “NEXT WHALE ERA” chapter with 3rd anniversary afterparty

Editors Picks

Challenged Athletes Foundation Receives Rings of Gold Award from U.S. Olympic & Paralympic Committee

October 1, 2026

CleanChoice Energy Closes Approximately $166M in Project Financing and Tax Equity for Two Solar Projects

October 1, 2026

Fabletics Launches Fabletics Reserve Credit Card, Expanding Value and Loyalty Perks to Its More than 2.7 Million Members

October 1, 2026

First Merchants Bank CEO Mark Hardwick to retire at the end of 2026 and President Mike Stewart to become President and CEO

October 1, 2026

Latest News

Primech Holdings (Nasdaq: PMEC) Unveils Primech Vision, Integrating a Multi-Robot Facility Fleet and Workforce on One Platform; Live Customer Demonstrations Begin October 2026

October 1, 2026

Police seek answers in crash that killed 2 elders, hurt 2 others on BC First Nation

October 1, 2026

An AI agent tried to hack Canadian government website, researchers say

October 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version